OG9 阅读 Q50

Choice B is the best answer. The first paragraph of Passage 1 quotes biochemist Kim Lewis of Northeastern University: "Pathogens are acquiring resistance faster than we can introduce new antibiotics, and this is causing a human health crisis." However, research conducted by Lewis has produced a drug called teixobactin, which has "proved effective at killing off a wide variety of disease-causing bacteria—even those that have developed immunity to other drugs," according to the second sentence of the second paragraph of Passage 1. Similarly, in the third sentence of the second paragraph of Passage 2, the author of the passage states that teixobactin "killed the tuberculosis bacterium, which is important because there is a real problem with resistant tuberculosis in the developing world." Therefore, both passages make the point that teixobactin could be useful in combating infections that are no longer responding to treatment with other antibiotics.
Choice A is incorrect because Passage 1 outlines the methodology used to produce teixobactin but doesn't offer it as a model for future development of antibiotics produced in laboratory environments. Passage 2 suggests that future development of antibiotics may draw on the methodology that Lewis and others developed, but the passage doesn't go so far as to suggest that teixobactin could be used to standardize this development. Choices C and D are incorrect because neither passage makes the point that teixobactin could be useful in controlling the spread of pathogenic soil fungi (choice C) or in shaping a new method of studying the effectiveness of antibiotics (choice D).